News2020-03-18T12:44:29+00:00
2702, 2020

Blueberry publishes latest peer-reviewed scientific paper

February 27th, 2020|Tags: , , |

Today, Blueberry Therapeutics published our latest peer-reviewed scientific paper. The paper entitled “Assessment of the nail penetration of antifungal agents, with different physico-chemical properties” was published in PLoS One (https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0229414) and describes our research into antifungal drugs and their ability [...]

1702, 2020

Blueberry Therapeutics extends a warm welcome to Clinical Science Lead

February 17th, 2020|

Blueberry Therapeutics are delighted to welcome Kerry Nield as Clinical Science Lead, with responsibility for clinical trial design and pipeline implementation including clinical scientific expertise, clinical strategy and product development planning. Kerry has over 17 years’ experience in pharmaceutical and [...]

302, 2020

Blueberry strengthens its analytical capabilities in the lab

February 3rd, 2020|

Today, Blueberry announces a significant growth in its analytical capabilities with the investment in a new triple quadrupole mass spectrometry - the Agilent Ultivo LC/MS system. This instrument offers the ability to perform high quality quantitative analyses in support of all [...]

302, 2020

A new Clinical Project Manager joins the Blueberry team

February 3rd, 2020|

Blueberry Therapeutics are delighted to welcome Sally Nguyen as a Clinical Project Manager, responsible for overseeing and managing the running of clinical trials from start up to completion/closeout. Sally possesses 12 years experience within Clinical Research, mainly [...]

1501, 2020

Blueberry Therapeutics Appoints Dr. Adrian Howd to Board of Directors

January 15th, 2020|Tags: , |

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial and therapeutic expertise.   Dr. Howd has over 20 years’ experience in the life science sector. He has held various private and public company Executive and Board roles in the UK, [...]

1511, 2019

Blueberry Therapeutics completes BB2603 Investigator meeting

November 15th, 2019|

The Blueberry Therapeutics project team along with CEO John Ridden, and their partner Iqvia Biotech, held an Investigator meeting in Vienna, Austria on November 8th 2019. The meeting was attended by over 50 site staff from both private and [...]

2110, 2019

Blueberry Therapeutics extends a warm welcome to Emma Leigh

October 21st, 2019|

Blueberry Therapeutics are delighted to welcome Emma Leigh as Medical Writing Lead, responsible for oversight of medical writing across nonclinical, clinical and regulatory deliverables. Prior to joining Blueberry, Emma has 18 years’ experience as a regulatory/medical writer within pharmaceutical companies [...]

107, 2019

Dave Edwards joins Blueberry Therapeutics

July 1st, 2019|

Blueberry Therapeutics are delighted to welcome Dave Edwards as Pharmaceutical Development Director, where he is responsible for CMC aspects of the manufacture of clinical supply materials through Phase II and III studies as well as subsequent commercialisation. Prior to this, [...]

406, 2019

Diane Lee joins the Blueberry team

June 4th, 2019|

We are delighted to welcome Diane Lee to the Blueberry Clinical Team. Diane has over 15 years’ experience in clinical research in different settings; Clinical Research Organisations, pharmaceutical companies and academic research.  She has a science background with a BSc [...]

802, 2019

CEO Dr. John Ridden talks Biotech Strategy & Nanomedicine

February 8th, 2019|

Blueberry Therapeutics’ CEO, Dr. John Ridden sat down with Pharmaphorum’s Dominic Tyer to talk strategy and bringing innovation to life through Blueberry Therapeutics' nanomedicine approach. Dr. Ridden also spoke about the concept of risk management in small biotech companies [...]

701, 2019

Blueberry Therapeutics welcomes Heather Davies!

January 7th, 2019|

Blueberry Therapeutics are delighted to welcome Heather Davies to the team as an Analytical Scientist. Heather is a biochemist by training and joins Blueberry after completing a post doc in France. She brings with her a wealth of experience from [...]

1912, 2018

Blueberry Therapeutics wins Bionow’s Company of the Year Award

December 19th, 2018|

Alderley Park, UK, 4thDecember 2018– Blueberry Therapeutics won the coveted ‘Company of the Year’ award after another remarkable year of progress and innovation. 2018 has seen many great achievements for Blueberry Therapeutics including the completion of £10m Series B [...]

1012, 2018

Noria joins Blueberry as a CRA

December 10th, 2018|

Blueberry Therapeutics are delighted to welcome Noria Mbuisa to the team! Noria joins us as a Clinical Research Associate, where she leads the review of study regulatory documents and data analysis. Noria has a Bachelor of Science Hons degree [...]

412, 2018

Blueberry Therapeutics welcomes Christian Little to the team

December 4th, 2018|

Blueberry Therapeutics would like to extend a warm welcome to Christian, who joins us with a wealth of experience as a Senior Clinical Project Manager. Christian has over 15 years’ experience in the pharmaceutical industry; three years in pipeline drug [...]

2311, 2018

CEO to attend the Dermatology Drug Development Summit in Boston

November 23rd, 2018|

Blueberry CEO, John Ridden, will be attending the 2nd Dermatology Drug Development Summit in Boston, 27-29th November 2018. The event is a unique industry-led conference focusing on innovating & accelerating the development amd commercialisation of dermatological medicines.

1110, 2018

CSO David Cook presents at ELRIG Drug Discovery Conference

October 11th, 2018|

David Cook presented at the recent ELRIG (European Laboratory Research and Innovation group) Drug Discovery Conference. David was invited to present in a workshop called “Build Biotech Success: A practical case study with CROs at Alderley Park”. The session focused [...]

1408, 2018

Blueberry Therapeutics Limited closes £10m funding to support development of nanomedicines portfolio

August 14th, 2018|

Alderley Park, UK, 14 August 2018– Blueberry Therapeutics Limited, (“Blueberry Therapeutics”) a drug discovery and development company focused on developing innovative nanomedicines for difficult to treat skin and nail infections, today announces that it has successfully completed its £10m [...]

2905, 2018

CEO attending BIO International, Boston

May 29th, 2018|

John Ridden, Blueberry CEO will be attending BIO International convention in Boston, 4th-7th June. 2018 is the 25th year for the BIO Convention, and attracts more than 16,000 biotechnology and pharma leaders who come together for one week of [...]

2004, 2018

Blueberry CEO, CSO and FD to attend BioTrinity London 23-25 April

April 20th, 2018|

John Ridden, David Cook and Mark Hollingworth will be attending BioTrinity London 23-25 April. BioTrinity is Europe’s leading biopartnering and investment conference, and is in its 12thconsecutive year. The theme for 2018 is “Next Generation Healthcare”. We look forward to [...]